The Next FDA Commissioner Must Be a Champion for Gene Therapies

Why It Matters

Regulatory predictability is the linchpin for capital flow and patient access; without it, the U.S. risks losing its edge in a transformative therapeutic arena. A commissioner committed to stable, science‑driven frameworks can safeguard both industry investment and patient outcomes.

Key Takeaways

• Marty Makary resigned, leaving FDA gene‑therapy roadmap uncertain.
• Orphan product rejection rates rose to ~30% in early 2026.
• Investment in gene therapies hinges on clear, consistent FDA pathways.
• Bipartisan legislation reauthorizes pediatric priority‑review voucher program.
• New commissioner must embed patient‑centered, adaptive trial frameworks.

Pulse Analysis

The abrupt departure of FDA Commissioner Marty Makary has amplified a growing sense of instability among gene‑therapy stakeholders. While the agency introduced a plausible‑mechanism framework to accommodate ultra‑rare diseases, the practical impact has lagged behind. Analysts note that orphan‑drug rejection rates have surged to about 30% this year, a stark jump from the historic 10% baseline. This regulatory turbulence not only stalls promising candidates but also erodes confidence among investors who rely on clear approval pathways to justify multi‑year, high‑cost development programs.

Capital allocation in the gene‑therapy sector is uniquely sensitive to policy signals. Manufacturing complexity and long development timelines mean that investors must forecast regulatory outcomes years in advance. When the FDA’s guidance appears inconsistent, funds gravitate toward therapies with more predictable pathways, including programs based overseas where regulators have steadily built advanced‑therapy frameworks. The recent bipartisan renewal of the pediatric priority‑review voucher program, signed into law by President Donald Trump, signals political will to sustain incentives, yet without a steady FDA hand the United States could cede its leadership to more agile jurisdictions.

Looking ahead, the next FDA commissioner will need to institutionalize a patient‑first, evidence‑flexible approach. This includes formalizing adaptive trial designs, leveraging real‑world evidence, and integrating natural‑history data to replace traditional large‑scale RCTs for ultra‑rare conditions. A durable, science‑driven regulatory architecture will reassure investors, keep pipelines domestic, and ensure that breakthrough gene therapies reach patients promptly. By aligning regulatory certainty with bipartisan legislative support, the U.S. can preserve its status as the world’s premier hub for biomedical innovation.